The MOHW objected to the criticism that it should continue to apply health insurance benefits of advanced bio-new drug Prolia (Denosumab), which treats osteoporosis, regardless of bone density figures. The MOHW said patients who still have low bone density measurements in follow-up tests after administering osteoporosis treatments such as Prolia continue to recognize their benefits regardless of time. On the 31st, the MOHW responded to a written question about the benefit standards for osteoporosis drugs by Rep. Lee Jong-sung, People Power Party.

Rep. Lee requested that the standard for osteoporosis treatments be changed to improve Prolia's benefit regardless of bone density levels. Improving the benefi